Patents by Inventor Shawn Michael Jennings

Shawn Michael Jennings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20250206818
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: December 2, 2024
    Publication date: June 26, 2025
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • Anti-LAG-3 antibodies and methods of use thereof
    Patent number: 12187795
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: January 7, 2025
    Assignee: AGENUS INC.
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • Anti-lag-3 antibodies and methods of use thereof
    Patent number: 11993651
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: May 28, 2024
    Assignee: AGENUS INC.
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • ANTI-CD73 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230416397
    Abstract: The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF?-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: May 26, 2023
    Publication date: December 28, 2023
    Inventors: Nicholas S. WILSON, Jeremy D. Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell
  • Anti-CD73 antibodies and methods of use thereof
    Patent number: 11692042
    Abstract: The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF?-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: July 4, 2023
    Assignee: AGENUS INC.
    Inventors: Nicholas Stuart Wilson, Jeremy Dale Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell
  • ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210171634
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: November 20, 2020
    Publication date: June 10, 2021
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210054074
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 25, 2021
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • Anti-LAG-3 antibodies and methods of use thereof
    Patent number: 10882908
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: January 5, 2021
    Assignee: Agenus Inc.
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • Anti-LAG-3 antibodies and methods of use thereof
    Patent number: 10844119
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: November 24, 2020
    Assignee: AGENUS INC.
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200362037
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: August 10, 2020
    Publication date: November 19, 2020
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • ANTI-CD73 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190352418
    Abstract: The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF?-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: March 8, 2019
    Publication date: November 21, 2019
    Inventors: Nicholas Stuart Wilson, Jeremy Dale Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell
  • ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180127499
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: October 11, 2017
    Publication date: May 10, 2018
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt